» Articles » PMID: 35900690

Amelioration of Intracerebroventricular Streptozotocin-induced Cognitive Dysfunction by Ocimum Sanctum L. Through the Modulation of Inflammation and GLP-1 Levels

Overview
Journal Metab Brain Dis
Publisher Springer
Specialties Endocrinology
Neurology
Date 2022 Jul 28
PMID 35900690
Authors
Affiliations
Soon will be listed here.
Abstract

DPP-4 inhibitors have been shown to reverse amyloid deposition in Alzheimer's disease (AD) patients with cognitive impairment. Ocimum sanctum L. leaves reported the presence of important phytoconstituents which are reported to have DPP-4 inhibitory activity. To investigate the effects of petroleum ether extract of Ocimum sanctum L. (PEOS) in Intracerebroventricular streptozotocin (ICV-STZ) induced AD rats. ICV-STZ (3 mg/kg) was injected bilaterally into male Wistar rats, while sham animals received the artificial CSF. The ICV-STZ-induced rats were administered with three doses of PEOS (100, 200, and 400 mg/kg, p.o.) for thirty days. All experimental rats were subjected to behaviour parameters (radial arm maze task and novel object recognition test), neurochemical parameters such as GLP-1, Aβ42, and TNF-α levels, and histopathological examination (Congo red staining) of the left brain hemisphere. PEOS significantly reversed the spatial learning and memory deficit exhibited by ICV-STZ-induced rats. Furthermore, PEOS also shows promising results in retreating Aβ deposition, TNF α, and increasing GLP-1 levels. The histopathological study also showed a significant dose-dependent reduction in amyloid plaque formation and dense granule in PEOS -treated rats as compared to the ICV-STZ induced rats (Negative control). The results show that extract of Ocimum sanctum L. attenuated ICV-STZ-induced learning and memory deficits in rats and has the potential to be employed in the therapy of AD.

Citing Articles

Dysregulated mTOR networks in experimental sporadic Alzheimer's disease.

de la Monte S, Tong M Front Cell Neurosci. 2024; 18:1432359.

PMID: 39386180 PMC: 11461251. DOI: 10.3389/fncel.2024.1432359.


Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.

Meng J, Yan R, Zhang C, Bai X, Yang X, Yang Y Lipids Health Dis. 2023; 22(1):219.

PMID: 38082288 PMC: 10712048. DOI: 10.1186/s12944-023-01985-y.

References
1.
Angelopoulou E, Piperi C . DPP-4 inhibitors: a promising therapeutic approach against Alzheimer's disease. Ann Transl Med. 2018; 6(12):255. PMC: 6046299. DOI: 10.21037/atm.2018.04.41. View

2.
Ayodele T, Rogaeva E, Kurup J, Beecham G, Reitz C . Early-Onset Alzheimer's Disease: What Is Missing in Research?. Curr Neurol Neurosci Rep. 2021; 21(2):4. PMC: 7815616. DOI: 10.1007/s11910-020-01090-y. View

3.
Calabro M, Rinaldi C, Santoro G, Crisafulli C . The biological pathways of Alzheimer disease: a review. AIMS Neurosci. 2021; 8(1):86-132. PMC: 7815481. DOI: 10.3934/Neuroscience.2021005. View

4.
Chen Y, Liang Z, Tian Z, Blanchard J, Dai C, Chalbot S . Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice. Mol Neurobiol. 2013; 49(1):547-62. PMC: 3948211. DOI: 10.1007/s12035-013-8539-y. View

5.
Correia S, Santos R, Perry G, Zhu X, Moreira P, Smith M . Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?. Ageing Res Rev. 2011; 10(2):264-73. PMC: 3056939. DOI: 10.1016/j.arr.2011.01.001. View